Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$19.0 million.

  • Ptc Therapeutics' Change in Accured Expenses fell 23616.58% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 214246.62%. This contributed to the annual value of -$33.3 million for FY2024, which is 16892.4% down from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Change in Accured Expenses is -$19.0 million, which was down 23616.58% from -$35.8 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Change in Accured Expenses ranged from a high of $36.8 million in Q4 2021 and a low of -$35.8 million during Q2 2025
  • Moreover, its 5-year median value for Change in Accured Expenses was $8.0 million (2023), whereas its average is $2.7 million.
  • Per our database at Business Quant, Ptc Therapeutics' Change in Accured Expenses soared by 72326.1% in 2021 and then crashed by 217102.12% in 2024.
  • Ptc Therapeutics' Change in Accured Expenses (Quarter) stood at $36.8 million in 2021, then fell by 29.36% to $26.0 million in 2022, then tumbled by 69.54% to $7.9 million in 2023, then plummeted by 461.34% to -$28.6 million in 2024, then skyrocketed by 33.47% to -$19.0 million in 2025.
  • Its Change in Accured Expenses stands at -$19.0 million for Q3 2025, versus -$35.8 million for Q2 2025 and $18.5 million for Q1 2025.